Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells

被引:32
|
作者
Angeletti, Francesca [1 ]
Fossati, Gianluca [2 ]
Pattarozzi, Alessandra [3 ]
Wurth, Roberto [3 ]
Solari, Agnese [3 ]
Daga, Antonio [4 ]
Masiello, Irene [1 ]
Barbieri, Federica [3 ]
Florio, Tullio [3 ]
Comincini, Sergio [1 ]
机构
[1] Univ Pavia, Dept Biol & Biotechnol, Pavia, Italy
[2] Italfarmaco SpA, Italfarmaco Res Ctr, Preclin Res Dept, Cinisello Balsamo, Italy
[3] Univ Genoa, Ctr Excellence Biomed Res, Dept Internal Med, Genoa, Italy
[4] IRCCS Azienda Osped Univ San Martino IST, Regenerat Med, Genoa, Italy
来源
关键词
glioblastoma multiforme; programmed cell death; histone deacetylase inhibitor; cancer stem cell; autophagy; HISTONE DEACETYLASE INHIBITORS; HDAC INHIBITORS; HEPATOMA-CELLS; IN-VITRO; APOPTOSIS; COMBINATION; GROWTH; IDENTIFICATION; HETEROGENEITY; TEMOZOLOMIDE;
D O I
10.3389/fnmol.2016.00107
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Increasing evidence highlighted the role of cancer stem cells (CSCs) in the development of tumor resistance to therapy, particularly in glioblastoma (GBM). Therefore, the development of new therapies, specifically directed against GBM CSCs, constitutes an important research avenue. Considering the extended range of cancer-related pathways modulated by histone acetylation/deacetylation processes, we studied the anti-proliferative and pro-apoptotic efficacy of givinostat (GVS), a pan-histone deacetylase inhibitor, on cell cultures enriched in CSCs, isolated from nine human GBMs. We report that GVS induced a significant reduction of viability and self-renewal ability in all GBM CSC cultures; conversely, GVS exposure did not cause a significant cytotoxic activity toward differentiated GBM cells and normal mesenchymal human stem cells. Analyzing the cellular and molecular mechanisms involved, we demonstrated that GVS affected CSC viability through the activation of programmed cell death pathways. In particular, a marked stimulation of macroautophagy was observed after GVS treatment. To understand the functional link between GVS treatment and autophagy activation, different genetic and pharmacological interfering strategies were used. We show that the up-regulation of the autophagy process, obtained by deprivation of growth factors, induced a reduction of CSC sensitivity to GVS, while the pharmacological inhibition of the autophagy pathway and the silencing of the key autophagy gene ATG7, increased the cell death rate induced by GVS. Altogether these findings suggest that autophagy represents a pro survival mechanism activated by GBM CSCs to counteract the efficacy of the anti-proliferative activity of GVS. In conclusion, we demonstrate that GVS is a novel pharmacological tool able to target GBM CSC viability and its efficacy can be enhanced by autophagy inhibitory strategies.
引用
下载
收藏
页数:19
相关论文
共 50 条
  • [1] Chemosensitization and radiosensitization effects of glioblastoma cells by the histone deacetylase inhibitor, givinostat (ITF2357) in glioblastoma cell models
    Gravina, G. L.
    Leoni, F.
    Benedetti, E.
    Delle Monache, S.
    Mancini, A.
    Angelucci, A.
    Di Cesare, E.
    Cimini, A. M.
    Porro, G.
    Festuccia, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S211 - S211
  • [2] Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma
    Francesco Marampon
    Flavio Leoni
    Andrea Mancini
    Ilaria Pietrantoni
    Silvia Codenotti
    Ferella Letizia
    Francesca Megiorni
    Giuliana Porro
    Elisabetta Galbiati
    Pietro Pozzi
    Paolo Mascagni
    Alfredo Budillon
    Roberto Maggio
    Vincenzo Tombolini
    Alessandro Fanzani
    Giovanni Luca Gravina
    Claudio Festuccia
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 393 - 409
  • [3] Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma
    Marampon, Francesco
    Leoni, Flavio
    Mancini, Andrea
    Pietrantoni, Ilaria
    Codenotti, Silvia
    Letizia, Ferella
    Megiorni, Francesca
    Porro, Giuliana
    Galbiati, Elisabetta
    Pozzi, Pietro
    Mascagni, Paolo
    Budillon, Alfredo
    Maggio, Roberto
    Tombolini, Vincenzo
    Fanzani, Alessandro
    Gravina, Giovanni Luca
    Festuccia, Claudio
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (02) : 393 - 409
  • [4] Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma
    Francesco Marampon
    Flavio Leoni
    Andrea Mancini
    Ilaria Pietrantoni
    Silvia Codenotti
    Letizia Ferella
    Francesca Megiorni
    Giuliana Porro
    Elisabetta Galbiati
    Pietro Pozzi
    Paolo Mascagni
    Alfredo Budillon
    Roberto Maggio
    Vincenzo Tombolini
    Alessandro Fanzani
    Giovanni Luca Gravina
    Claudio Festuccia
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 2411 - 2411
  • [5] The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis
    Celesia, Adriana
    Notaro, Antonietta
    Franzo, Marzia
    Lauricella, Marianna
    D'Anneo, Antonella
    Carlisi, Daniela
    Giuliano, Michela
    Emanuele, Sonia
    BIOMEDICINES, 2022, 10 (08)
  • [6] Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma (vol 145, pg 393, 2019)
    Marampon, Francesco
    Leoni, Flavio
    Mancini, Andrea
    Pietrantoni, Ilaria
    Codenotti, Silvia
    Ferella, Letizia
    Megiorni, Francesca
    Porro, Giuliana
    Galbiati, Elisabetta
    Pozzi, Pietro
    Mascagni, Paolo
    Budillon, Alfredo
    Maggio, Roberto
    Tombolini, Vincenzo
    Fanzani, Alessandro
    Gravina, Giovanni Luca
    Festuccia, Claudio
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (09) : 2411 - 2411
  • [7] ITF2357, a novel historic deacetylase inhibitor, demonstrates significant apoptotic activity against human multiple myeloma cells
    Kline, Michael
    Donovan, Kathleen A.
    Lust, John A.
    BLOOD, 2007, 110 (11) : 271B - 271B
  • [8] MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma
    Zappasodi, Roberta
    Cavane, Alessandra
    Iorio, Marilena V.
    Tortoreto, Monica
    Ruggiero, Giusi
    Magni, Michele
    Carlo-Stella, Carmelo
    Tagliabue, Elda
    Zunino, Franco
    Croce, Carlo M.
    Gianni, Alessandro M.
    Di Nicola, Massimo
    BLOOD, 2011, 118 (21) : 1174 - 1174
  • [9] Long non-coding RNA H19 enhances the pro-apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells
    Zichittella, Chiara
    Loria, Marco
    Celesia, Adriana
    Di Liberto, Diana
    Corrado, Chiara
    Alessandro, Riccardo
    Emanuele, Sonia
    Conigliaro, Alice
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [10] Inhibition of autophagy potentiates the proliferation inhibition activity of microRNA-7 in human hepatocellular carcinoma cells
    Wang, Yanna
    Wang, Qiaoling
    Song, Jiqing
    ONCOLOGY LETTERS, 2017, 14 (03) : 3566 - 3572